Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AXSM
SellHot AirAxsome Therapeutics, Inc. · Healthcare · United States · $10.4B · Avg Vol: $134M/d
COMPANY DESCRIPTION
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, with a pipeline addressing areas like depression, migraine, and narcolepsy. The company's competitive advantage stems from its innovative product candidates and proprietary technology designed to enhance drug efficacy and safety. Axsome seeks to address significant unmet medical needs in large and growing CNS markets, holding multiple FDA-approved products.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.0M | 270.6M | 385.7M | 638.5M | 133.7% | 776.6M | 966.2M | 1.6B | 56.4% |
| EPS | -4.60 | -5.27 | -5.99 | -3.68 | — | -3.75 | -2.64 | 5.03 | — |
| Shares | 43.5M | 47.4M | 48.7M | 50.9M | +17.0% | 52.4M | — | — | — |
| Debt | 94.7M | 186.4M | 193.0M | 218.1M | 32.1% | 224.7M | — | — | — |
| Equity | 109.6M | 191.0M | 57.0M | 88.3M | -6.9% | — | — | — | — |
| Op CF | -116.5M | -145.1M | -128.4M | -93.4M | — | -71.3M | — | — | — |
| Inv CF | -53.7M | -0.6M | -0.3M | -0.5M | — | — | — | — | — |
| Fin CF | 284.6M | 331.0M | 57.8M | 101.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AXSM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc.(you) | $10.4B | 25 | Sell |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 24 | Sell |
| CYTK | Cytokinetics, Incorporated | $10.0B | 22 | Sell |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.0B | 26 | Sell |
| KYMR | Kymera Therapeutics, Inc. | $9.7B | 21 | Sell |
| PCVX | Vaxcyte, Inc. | $8.9B | 28 | Sell |
| IBRX | ImmunityBio, Inc. | $8.5B | 22 | Sell |
| SYRE | Spyre Therapeutics, Inc. | $8.0B | 23 | Sell |
| PRAX | Praxis Precision Medicines, Inc. | $9.6B | 31 | Sell |
| IMVT | Immunovant, Inc. | $8.5B | 21 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%